Moderna’s COVID-19 vaccine, mRNA-1273, demonstrated 93% efficacy through 6 months after administration of the second dose.

The efficacy data was based on a final analysis of the phase 3 COVE study ( Identifier: NCT04470427) which evaluated the efficacy and safety of the mRNA-1273 vaccine in more than 30,000 adults aged 18 years and older. The analysis showed that the vaccine “remains durable” through 6 months relative to its initial efficacy of 94.1% reported in November 2020.

Additionally, the Company is evaluating 3 different mRNA booster candidates in a phase 2 study, which included mRNA-1273, investigational mRNA-1273.351, and investigational mRNA-1273.211. Vaccination with 50mcg of the booster candidates have shown to elicit robust antibody responses against the wildtype D614G COVID-19 strain and against variants of concern including Gamma (P.1); Beta (B.1.351); and Delta (B.1.617.2). The data have been submitted to a peer-reviewed journal for publication.

Continue Reading

“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” said Stéphane Bancel, CEO of Moderna.

The Company has also filed for an Emergency Use Authorization (EUA) for the mRNA-1273 vaccine in adolescents aged 12 to 17 years based on data from its phase 2/3 TeenCOVE study ( Identifier: NCT04649151).

Moreover, the vaccine is being evaluated in an ongoing phase 2 KidCOVE study ( Identifier: NCT04796896) in patients 6 months to 11 years of age and in an ongoing phase 3 COVE Transplant study ( Identifier: NCT04860297) in adults with a kidney or liver transplant.


Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates. News release. Moderna, Inc. Accessed August 6, 2021.

This article originally appeared on MPR